Radoslaw Pracon1, Sripal Bangalore2, Zofia Dzielinska2, Marek Konka2, Cezary Kepka2, Mariusz Kruk2, Edyta Kaczmarska-Dyrda2, Joanna Petryka-Mazurkiewicz2, Sebastian Bujak2, Mateusz Solecki2, Agnieszka Pskit2, Agnieszka Dabrowska2, Bartosz Sieradzki2, Andrzej Plonski2, Witold Ruzyllo2, Adam Witkowski2, Marcin Demkow2. 1. From the Coronary and Structural Heart Diseases Department (R.P., Z.D., C.K., M.K., E.K.-D., J.P.-M., S.B., M.S., A.P., A.D., B.S., A.P., M.D.), Congenital Heart Diseases Department (M.K.), and Interventional Cardiology and Angiology Department (A.W.), Institute of Cardiology, Warsaw, Poland; Department of Medicine, New York University School of Medicine (S.B.); and Coronary and Structural Heart Diseases Department, Institute of Cardiology, Warsaw, Poland (W.R.). radekpracon@yahoo.pl. 2. From the Coronary and Structural Heart Diseases Department (R.P., Z.D., C.K., M.K., E.K.-D., J.P.-M., S.B., M.S., A.P., A.D., B.S., A.P., M.D.), Congenital Heart Diseases Department (M.K.), and Interventional Cardiology and Angiology Department (A.W.), Institute of Cardiology, Warsaw, Poland; Department of Medicine, New York University School of Medicine (S.B.); and Coronary and Structural Heart Diseases Department, Institute of Cardiology, Warsaw, Poland (W.R.).
Abstract
BACKGROUND: Device-related thrombus (DRT) after left atrial appendage occlusion is a worrisome finding with little knowledge about when to expect it and how to prevent it. This study sought to investigate correlates of DRT after left atrial appendage occlusion, its time of diagnosis, and particularly, association with postimplantation dual antiplatelet therapy duration. METHODS AND RESULTS: Consecutive patients (n=102) after left atrial appendage occlusion with AMPLATZER Cardiac Plug/Amulet (n=59) or WATCHMAN (n=43) were included in a prospective registry (October 2011-May 2016). Follow-up was done at 1.5, 3 to 6, and 12 months postimplantation. DRT was classified as early (at 1.5 month), late (at 3-6 month), or very late (at 12-month follow-up). Postimplantation dual antiplatelet therapy was recommended for 30 to 180 days and decided independently by attending physicians. Final analysis included 99 patients, 42 (42.4%) females, with median CHA2DS2-VASc of 4.0 (interquartile range [IQR], 3.0-5.0) and median HAS-BLED score of 2.0 (IQR, 1.0-3.0). DRTs were observed in 7 (7.1%) patients: 2 (28.6%) early, 2 (28.6%) late, and 3 (42.9%) very late. When compared with patients without DRT, those with DRT presented more often with a history of prior thromboembolism (5 [71.4%] versus 28 [30.4%]; P=0.04), had lower left ventricular ejection fraction (50.0 [IQR, 35.0-55.0] versus 60.0 [IQR, 55.0-66.0]; P<0.01), and had greater proportion of patients with deep device implantation (6 [85.7%] versus 36 [39.1%]; P=0.04) and with larger devices implanted (30.0 mm [IQR, 27.0-33.0] versus 25.0 mm [IQR, 24.0-28.0]; P<0.01). Postimplantation dual antiplatelet therapy duration was not different between the 2 groups (12.4 weeks [IQR, 6.0-49.7] with DRT versus 13.0 weeks [IQR, 7.3-26.0] without DRT; P=0.77). CONCLUSIONS: In this real-world series, DRT was observed early, late, and very late after left atrial appendage occlusion. It was related to patient and procedural characteristics but not to postimplantation dual antiplatelet therapy duration.
BACKGROUND: Device-related thrombus (DRT) after left atrial appendage occlusion is a worrisome finding with little knowledge about when to expect it and how to prevent it. This study sought to investigate correlates of DRT after left atrial appendage occlusion, its time of diagnosis, and particularly, association with postimplantation dual antiplatelet therapy duration. METHODS AND RESULTS: Consecutive patients (n=102) after left atrial appendage occlusion with AMPLATZER Cardiac Plug/Amulet (n=59) or WATCHMAN (n=43) were included in a prospective registry (October 2011-May 2016). Follow-up was done at 1.5, 3 to 6, and 12 months postimplantation. DRT was classified as early (at 1.5 month), late (at 3-6 month), or very late (at 12-month follow-up). Postimplantation dual antiplatelet therapy was recommended for 30 to 180 days and decided independently by attending physicians. Final analysis included 99 patients, 42 (42.4%) females, with median CHA2DS2-VASc of 4.0 (interquartile range [IQR], 3.0-5.0) and median HAS-BLED score of 2.0 (IQR, 1.0-3.0). DRTs were observed in 7 (7.1%) patients: 2 (28.6%) early, 2 (28.6%) late, and 3 (42.9%) very late. When compared with patients without DRT, those with DRT presented more often with a history of prior thromboembolism (5 [71.4%] versus 28 [30.4%]; P=0.04), had lower left ventricular ejection fraction (50.0 [IQR, 35.0-55.0] versus 60.0 [IQR, 55.0-66.0]; P<0.01), and had greater proportion of patients with deep device implantation (6 [85.7%] versus 36 [39.1%]; P=0.04) and with larger devices implanted (30.0 mm [IQR, 27.0-33.0] versus 25.0 mm [IQR, 24.0-28.0]; P<0.01). Postimplantation dual antiplatelet therapy duration was not different between the 2 groups (12.4 weeks [IQR, 6.0-49.7] with DRT versus 13.0 weeks [IQR, 7.3-26.0] without DRT; P=0.77). CONCLUSIONS: In this real-world series, DRT was observed early, late, and very late after left atrial appendage occlusion. It was related to patient and procedural characteristics but not to postimplantation dual antiplatelet therapy duration.
Authors: Mohammed Osman; Tatiana Busu; Khansa Osman; Safi U Khan; Matthew Daniels; David R Holmes; Mohamad Alkhouli Journal: JACC Clin Electrophysiol Date: 2020-01-29
Authors: Roberto Galea; Federico De Marco; Adel Aminian; Nicolas Meneveau; Frederic Anselme; Christoph Gräni; Adrian T Huber; Emmanuel Teiger; Xavier Iriart; Marco Angelillis; Nicolas Brugger; Alessandro Spirito; Noé Corpataux; Anna Franzone; Pascal Vranckx; Urs Fischer; Giovanni Pedrazzini; Francesco Bedogni; Stephan Windecker; Lorenz Räber; Marco Valgimigli Journal: J Cardiovasc Transl Res Date: 2021-04-21 Impact factor: 4.132
Authors: Fareed Moses S Collado; Claudia M Lama von Buchwald; Christina K Anderson; Nidhi Madan; Hussam S Suradi; Henry D Huang; Hani Jneid; Clifford J Kavinsky Journal: J Am Heart Assoc Date: 2021-10-20 Impact factor: 5.501
Authors: Ali Hamadanchi; Shun Ijuin; Franz Haertel; Tarek Bekfani; Julian Westphal; Marcus Franz; Sven Moebius-Winkler; P Christian Schulze Journal: J Clin Med Date: 2022-02-18 Impact factor: 4.241